Consolidated Consolidated Statements of Operations (Current Period Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 3,748,000	$ 3,508,000
General and administrative	3,232,000	3,590,000
Total operating expenses	6,980,000	7,098,000
Operating loss	(6,980,000)	(7,098,000)
Interest income	1,138,000	850,000
Other expense, net	(36,000)	(33,000)
Loss before income taxes	(5,878,000)	(6,281,000)
Income taxes benefit	0	0
Net loss	$ (5,878,000)	$ (6,281,000)
Net loss per share of common stock - basic (in dollars per share)	$ (0.05)	$ (0.05)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.05)	$ (0.05)
Weighted average shares outstanding used to compute net loss per share- basic (in shares)	125,319,778	126,624,110
Weighted average shares outstanding used to compute net loss per share - diluted (in shares)	125,319,778	126,624,110